Surmount Laboratories Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 27-06-2024
- Paid Up Capital ₹ 2.36 Cr
as on 27-06-2024
- Company Age 28 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 40.90 Cr
as on 27-06-2024
- Satisfied Charges ₹ 9.80 Cr
as on 27-06-2024
- Revenue -1.84%
(FY 2023)
- Profit 81.23%
(FY 2023)
- Ebitda 24.28%
(FY 2023)
- Net Worth 53.87%
(FY 2023)
- Total Assets 14.37%
(FY 2023)
About Surmount Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 2.36 Cr.
The company currently has active open charges totaling ₹40.90 Cr. The company has closed loans amounting to ₹9.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dhirendra Mehta, Kavit Mehta, and Minesh Mehta serve as directors at the Company.
- CIN/LLPIN
U24230MH1996PTC098511
- Company No.
098511
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Surmount Laboratories?
Board Members(3)
Financial Performance and Corporate Structure Insights of Surmount Laboratories.
Surmount Laboratories Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.84% decrease. The company also saw a substantial improvement in profitability, with a 81.23% increase in profit. The company's net worth Soared by an impressive increase of 53.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Surmount Laboratories?
In 2023, Surmount Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Surmount Formulations Private Limited
Active
4 years Dhirendra Mehta and Kavit Mehta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Dec 2023 | ₹5.00 M | Open |
Others Creation Date: 15 Nov 2022 | ₹15.00 Cr | Open |
Others Creation Date: 04 Oct 2022 | ₹6.00 Cr | Open |
How Many Employees Work at Surmount Laboratories?
Surmount Laboratories has a workforce of 19 employees as of Apr 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Mar 27, 2018, Surmount Laboratories has raised a total of ₹ 2.47 Cr, with the most recent deal valued at ₹ 3 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
